The Bottom Line Although AOD-9604, MOTS-c, Tesamorelin, Semaglutide, and Tirzepatide are often discussed together, they serve very different purposes
It was found that oral semaglutide was effective in reducing hemoglobin A1c, achieving glycemic control, and reducing body weight
Conditions like Achilles tendinopathy, rotator cuff injuries, and knee ligament damage are commonly mentioned
In particular, SGLT2 inhibitors have shown a strong impact on a high number of risk factors
The efficacy and safety of the new GLP-1 medicines continues to garner interest and will be discussed #ADA2024 Here is an updated safety-focused summary of the field and where it might be headed @DiabetesCareADA #T2D #obesity pic.twitter.com/rtEQYtHQG0 Daniel J Drucker (@DanielJDrucker) June 6, 2024 Investigational GLP-1 medicines in the clinic Late-stage investigational GLP-1 medicines for type 2 diabetes and obesity include new molecules like retatrutide and orforglipron, showing potential differentiation from semaglutide and tirzepatide through better tolerability, greater weight loss, Hb A 1c reduction, and targeted outcomes
Some weight regain is possible without proper lifestyle support, which is why we focus on sustainable habits and long-term metabolic health